Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.
Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.
The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.
Researchers presented updated findings from the GLOW trial.
Vaccine responses were evaluated after dose 1 for 158 CLL patients, after dose 2 for 506 patients, and after dose 3 for 66 patients.